U.S. Health Chief Says No Evidence Linking Tylenol to Autism
The U.S. Health Secretary stated that there is insufficient scientific evidence to support claims linking acetaminophen (Tylenol) use during pregnancy to autism, pushing back against a surge of lawsuits and public concern. The clarification follows online speculation and legal actions alleging that prenatal exposure to the common pain reliever increases autism risk in children. Federal health officials warned that misinformation may lead pregnant women to avoid medically necessary pain or fever treatment, which could pose greater danger to maternal and fetal health. The statement emphasised the need for evidence-based guidance and noted that ongoing research has not established causation. Regulators are monitoring emerging data but reiterated that current evidence does not justify changes to prescribing recommendations. The remarks aim to curb public alarm and reinforce reliance on scientifically validated medical advice.
Looking for chemical products? Let suppliers reach out to you!
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
West Asia Tensions Squeeze Pharma Raw Materials
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
Recommend Reading
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
Germany Passes Healthcare Reform, Multinational Drugmakers Face 15.5% Mandatory Discount
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
Raw Material Side Shows Resilience—PTA Prices Surge Over 3% in a Single Day
-
China’s EVA Market Has Entered a Downward Trend Since May
-
Antidumping Pressure Hits the Chemical Chain as Chinese Exports Face Higher Barriers in Europe
-
China's Natural Rubber Market Weakly Consolidates
-
Cost Benefits Drive a Noticeable Price Increase in Polyester Staple Fiber